Overview

Versiti has acquired Quantigen to further expand their clinical trial expertise and service offering.

Significance

Of the ~$170 billion global diagnostic testing market, the bioanalytical and esoteric testing segments comprise nearly 25%^1,2, driven by the growing use of biotechnology in both the diagnosis and treatment of diseases. Increasing demand for precision and personalized medicine is driving providers, clinical researchers, and pharma sponsors to demand highly-specialized diagnostic services to support both patient care and a growing biotech drug development pipeline.

Indiana-based Quantigen was founded in 2009 as an expert methods development laboratory; focused specifically on high value application needs supporting molecular assay development. Their combination of skill and knowledge results in improved patient outcomes, higher quality services and reduced cost of care for hospitals, blood centers, hospital systems, research and educational institutions, and other health care providers. Quantigen’s range of services supporting preclinical/clinical research and clinical diagnostics made it a natural fit to strengthen Versiti’s existing clinical laboratory service offering.

Crosstree’s Role

Crosstree’s granular diagnostic testing expertise helped Versiti identify Quantigen as the ideal acquisition target to expand its service offering through:

• Leveraging deep knowledge of the diagnostics and tools sector to evaluate the capabilities of potential targets to determine the optimal fit to accelerate growth
• Developing and evaluating growth strategies and conducting feasibility and ROI analyses
• Managing the due diligence process timeline to bring the transaction to a successful outcome